Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial.
Eggermont AMM, Rutkowski P, Dutriaux C, Hofman-Wellenhof R, Dziewulski P, Marples M, Grange F, Lok C, Pennachioli E, Robert C, van Akkooi ACJ, Bastholt L, Minisini A, Marshall E, Salès F, Grob JJ, Bechter O, Schadendorf D, Marreaud S, Kicinski M, Suciu S, Testori AAE. Eggermont AMM, et al. Among authors: kicinski m. Eur J Cancer. 2020 Jul;133:94-103. doi: 10.1016/j.ejca.2020.04.015. Epub 2020 May 26. Eur J Cancer. 2020. PMID: 32470710 Clinical Trial.
10-day vs 5-day decitabine: equivalence cannot be concluded.
Huls G, Suciu S, Wijermans P, Kicinski M, Lübbert M. Huls G, et al. Among authors: kicinski m. Lancet Haematol. 2019 Apr;6(4):e177. doi: 10.1016/S2352-3026(19)30024-9. Lancet Haematol. 2019. PMID: 30926076 No abstract available.
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi AC, Suciu S, Robert C. Eggermont AMM, et al. Among authors: kicinski m. Eur J Cancer. 2019 Jul;116:148-157. doi: 10.1016/j.ejca.2019.05.020. Epub 2019 Jun 11. Eur J Cancer. 2019. PMID: 31200321 Clinical Trial.
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.
Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio M, Hosein F, de Pril V, Kicinski M, Suciu S, Testori A. Eggermont AMM, et al. Among authors: kicinski m. Eur J Cancer. 2019 Sep;119:1-10. doi: 10.1016/j.ejca.2019.07.001. Epub 2019 Aug 7. Eur J Cancer. 2019. PMID: 31400634 Clinical Trial.
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.
Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Krepler C, Ibrahim N, Marreaud S, van Akkooi A, Robert C, Suciu S. Eggermont AMM, et al. Among authors: kicinski m. JAMA Oncol. 2020 Apr 1;6(4):519-527. doi: 10.1001/jamaoncol.2019.5570. JAMA Oncol. 2020. PMID: 31895407 Free PMC article. Clinical Trial.
Comment on "Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram".
Olofsson Bagge R, Kicinski M, Faries MB, Gyorki DE, Isaksson K, Katsarelias D, Lo S, Moncrieff M, Spillane A, Suciu S, van Akkooi A. Olofsson Bagge R, et al. Among authors: kicinski m. J Clin Oncol. 2020 Sep 20;38(27):3233-3234. doi: 10.1200/JCO.20.01680. Epub 2020 Jul 23. J Clin Oncol. 2020. PMID: 32701414 No abstract available.
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C. Eggermont AMM, et al. Among authors: kicinski m. J Clin Oncol. 2020 Nov 20;38(33):3925-3936. doi: 10.1200/JCO.20.02110. Epub 2020 Sep 18. J Clin Oncol. 2020. PMID: 32946353 Free PMC article. Clinical Trial.
Reply to E. Hindié.
Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C. Eggermont AMM, et al. Among authors: kicinski m. J Clin Oncol. 2021 Mar 10;39(8):944-946. doi: 10.1200/JCO.20.03463. Epub 2021 Jan 25. J Clin Oncol. 2021. PMID: 33492998 No abstract available.
68 results